The ROR1 FC data generated from CLL and HCL samples was based only on a membrane signature considering that membrane distribution is required to assess ROR1 as a tumour target for new therapeutic modalities such as ADC, TCE, or CAR-T [1, 10]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.